Allogene Therapeutics, Inc.
ALLONASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $440.77M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.04$4.46
- Volume (live)
- -
- Avg. volume (3M)
- 5.89M
Allogene Therapeutics (ALLO) Stock Price & Financial Analysis
Allogene Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1.29 - $1.34 |
|---|---|
| 52-Week High | $4.46 |
| 52-Week Low | $1.04 |
| Open | $1.34 |
| Volume (last close) | 4.92M |
| Average Volume (3M) | 5.89M |
| Revenue (TTM) | 4.64M |
|---|---|
| Net Income (TTM) | -165.49M |
| Free Cash Flow (TTM) | -102.60M |
| EPS (TTM) | −$0.65 |
| Profit Margin | -3566.68% |
| Operating Margin | -3886.14% |
| Return on Equity (ROE) | -37.94% |
| Debt to Equity | 0.16 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 440.77M |
|---|---|
| Shares Outstanding | 328.93M |
| Price to Sales (P/S) | 94.99 |
| Price to Book (P/B) | 1.01 |
| EV/EBITDA | -3.01 |
| 50-Day MA | $1.81 |
|---|---|
| 200-Day MA | $1.99 |
| 1-Year Change | +8.94% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Allogene Therapeutics at a Glance
As of the Oct 16, 2026 close, Allogene Therapeutics (ALLO) has a market capitalization of $440.77M. The stock trades at 95.0× sales. Over the trailing twelve months it lost $165.49M on revenue of $4.64M and burned $102.60M of free cash flow. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $38.63M in cash and securities against $70.35M of debt, a net debt position of $31.73M.
Allogene Therapeutics does not currently pay a dividend.
The share price is up 8.9% over the past year. At $1.31 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $1.04 to $4.46, below its 200-day moving average of $1.99.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $10.25, 682.4% above the Oct 16, 2026 close.
Frequently Asked Questions About Allogene Therapeutics
What is the current stock price for ALLO?
As of the Oct 16, 2026 close, ALLO stock trades at $1.31. The 52-week range is $1.04–$4.46, with a day range of $1.29–$1.34.
What is the P/E ratio for ALLO?
The P/E ratio (Price-to-Earnings) for ALLO is shown in the Key Statistics section. This valuation metric helps compare Allogene Therapeutics, Inc. to industry peers.
Does ALLO pay dividends?
Allogene Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for ALLO?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for ALLO is Buy. The average 12-month price target is $10.25, a 682.4% upside from the Oct 16, 2026 close of $1.31.
What is the market cap of ALLO?
As of the Oct 16, 2026 close, Allogene Therapeutics's market capitalization is $430.9M, classifying it as a small-cap company. Allogene Therapeutics operates in the Healthcare sector within the Biotechnology industry.